Pharma Surge
Pharma Surge
Intelligence Layer
🌍·Jan 23Devices

CHEMBIO ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS TnT ASSAY FOLLOWING BREAKTHROUGH DEVICE DESIGNATION

Publisher

C
Chembio Diagnostics, Inc.

Global

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Chembio Diagnostics, Inc.
Region
Global
Scope
Devices
Published
January 23, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on chembio.com

Leave the platform to read the original full article on the publisher site.

Source: Chembio Diagnostics, Inc.

Scope: Devices

Open original article
CHEMBIO ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS TnT ASSAY FOLLOWING BREAKTHROUGH DEVICE DESIGNATION | Pharma Surge